Unilife Develops Proprietary Portfolio of Wearable Subcutaneous Infusion Devices for the Self-Administration of Large Volume Drugs by Patients--The world's first and only wearable, disposable ...

The goal of developing a subcutaneous ICD was to overcome some of the problems that are associated with transvenous leads in conventional ICDs. 3,6–11,14,15,40 Such a device could potentially ...

As part of the agreement, Ypsomed will customize and supply YpsoMate 2.25 patient-administered delivery devices to support Viridian’s development of investigational subcutaneous therapy ...

The global subcutaneous drug delivery devices market is expected to reach US$ 17,290.47 Mn in 2027 from US$ 9,243.80 in 2018. The market is estimated to grow with a CAGR of 7.4% from 2019-2027.

Dublin, April 01, 2025 (GLOBE NEWSWIRE) -- The "Subcutaneous Biologics Market, Industry Trends and Global Forecasts to 2035: Type of Biologic, Type of Therapy, Method of Administration ...

DUBLIN, Dec. 21, 2017 /PRNewswire/ --The 'On-Body Subcutaneous Injection Systems' report has been added to Research and Markets' offering.

LifeSite Device. The LifeSite subcutaneous access system allows immediate hemodialysis after implantation. The device consists of a silicone cannula, which is placed in a central venous location ...

The new retrospective study adds to a growing body of research showing benefits of subcutaneous anchor devices, including a 2020 study that showed reduced risk of bloodstream infections and a 2022 ...

A new study on securement for central vascular access devices (CVAD) suggests that subcutaneous anchor securement systems (SASS) are shown to be more effective at keeping central catheters in ...